Chimerix Inc - ESG Rating & Company Profile powered by AI
If you work at Chimerix Inc and you wish to licence your Sustainability aseessment, please contact us. This report of Chimerix Inc was prepared by All Street Sevva using proprietary AI. This webpage contains a free Sustainability assessment for Chimerix Inc.
Chimerix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 1.6 and governance score of 1.6.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1631 | Viewbix Inc | 1.8 | Low |
1631 | dorsaVi Ltd | 1.8 | Low |
1682 | Chimerix Inc | 1.7 | Low |
1682 | C4 Therapeutics Inc | 1.7 | Low |
1682 | Abcellera Biologics Inc | 1.7 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Chimerix Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Chimerix Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Chimerix Inc report the average age of the workforce?
Sign up for free to unlockDoes Chimerix Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Chimerix Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Chimerix Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Chimerix Inc offer flexible work?
Sign up for free to unlockDoes Chimerix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Chimerix Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Chimerix Inc conduct supply chain audits?
Sign up for free to unlockDoes Chimerix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Chimerix Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Chimerix Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Chimerix Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Chimerix Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Chimerix Inc disclose water use targets?
Sign up for free to unlockDoes Chimerix Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Chimerix Inc have a product recall in the last two years?
Sign up for free to unlockDoes Chimerix Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Chimerix Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Chimerix Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Chimerix Inc disclose parental leave metrics?
Sign up for free to unlockDoes Chimerix Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Chimerix Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Chimerix Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Chimerix Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Chimerix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Chimerix Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Chimerix Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Chimerix Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Chimerix Inc disclose its waste policy?
Sign up for free to unlockDoes Chimerix Inc report according to TCFD requirements?
Sign up for free to unlockDoes Chimerix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Chimerix Inc disclose energy use targets?
Sign up for free to unlockDoes Chimerix Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Chimerix Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Chimerix Inc
These potential risks are based on the size, segment and geographies of the company.
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.